Here are five things to know:
1. All patients in the study had sports-related injuries leading to complete rupture of their ACL, and all received Cytori Cell Therapy to reconstruct the ACL.
2. The presented data includes safety, feasibility, patient-reported outcomes related to activity levels and pain as well as serial MRI of the knee through one year.
3. Researchers compared the data to a historical control group of similar patients treated at the same center by the same surgical team using the same procedure without supplementation of Cytori Cell Therapy.
4. Dr. Cugat currently serves as president of the Medical Council at the Catalan Mutual Insurance of Football under the Royal Spanish Football Federation.
5. Cytori Therapeutics is a San Diego-based late stage cell therapy company.
More articles on devices and implants:
Medtronic expects surgical robot to generate ‘meaningful’ revenue in 2019: 7 key points on the device company’s next steps
How effective are electrical bone stimulators for bone healing? Dr. Mohit Bhandari weighs in with new evidence
Avadim introduces Theraworx sports medicine technology — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
